#42 Dr Rob Coleman - Competing against Pfizer in the covid-19 vaccine race with Codagenix

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

#42 Dr Rob Coleman - Competing against Pfizer in the covid-19 vaccine race with Codagenix

無料で聴く

ポッドキャストの詳細を見る

What: Codagenix is a clinical-stage biotechnology company that has raised over $25 million USD in funding to develop vaccine products against influenza, the respiratory syncytial virus, dengue virus and many others. Codagenix uses a computer-based algorithm called SAVE (Synthetic Attenuated Virus Engineering) that designs viral genomes identical to wild type strains at the amino acid level, but which make less protein in human cells. These highly attenuated viruses are then used to develop vaccines for human use. Who: Rob is a trained virologist and entrepreneur, whose pivotal advances in synthetic biology have been noted in peer reviewed journals such as Science, Nature Biotechnology, and PNAS. We talk about: Competing in the covid-19 vaccine race with Pfizer, diversifying in business, and metaphorically building the plane while you’re flying. 📝 You can also now read the accompanying "podnotes" to the episode on Substack, where key insights from every conversation will be shared for those who prefer short and snappy takeaways: founderskeepers.substack.com Find out more: www.founders-keepers.com Instagram: @founderskeepers.pod Twitter: @founders.pod LinkedIn: https://www.linkedin.com/company/founders-keepers-podcast Get in touch: hi@founders-keepers.com

まだレビューはありません